Categories:

• Agriculture and Forestry
• Automotive
• Biotechnology and Pharmaceuticals
• Chemicals
• Construction and Maintenance
• Consumer Goods and Services
• Electronics and Electrical
• Energy and Environment
• Food and Related Products
• Industrial Goods and Services
• Information Technology
• Materials
• Real Estate
• Telecommunications
• Textiles and Nonwovens
• Transportation and Logistics

Popular Tags:

• player
• mp4
• mp4 player
• screen
• player screen
• screen mp4
• 4gb
• player 4gb
• 4gb mp4
• card
• slot
• player card
• 18inch
• inch
• 15inch
• inch mp4
• inch player
• flash
• style
• builtin

Home › trial

 

Tag: trial

Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress

2013-04-23 12:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language:  English Contact HTML:  MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: the data international updated

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

2013-04-22 13:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language:  English Contact HTML:  MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: c agreement trial combination

Russian accused of threatening air steward to blow up plane claims trial

2013-04-22 13:17:25| Airlines - Topix.net

A 26-year-old Russian man accused of threatening an air steward that he would blow up a Singapore Airlines plane is claiming trial.

Tags: air trial claims russian

Nortel European creditors appeal trial decision

2013-04-19 02:00:00| Total Telecom industry news

Move will likely lead to even more delays to former vendor's long-running bankruptcy case.

Tags: decision trial european appeal

UPDATE 2-Vertex shares up after successful cystic fibrosis trial

2013-04-19 01:15:33| Biotech - Topix.net

ROB Insight is The Globe and Mail's exclusive feature led by a team of award-winning editors and writers who provide you with in-depth analysis on breaking business news and the issues that matter most.

Tags: update trial successful shares

Sites : [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] next »